跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Naphthyridine Inhibitor
首页
药物
Naphthyridine Inhibitor
Experimental
Small Molecule
Naphthyridine Inhibitor
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
17
H
15
N
5
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US 2005124604 A1
申请人: SIRCAR JAGADISH
优先权: 2003
CN
US
4 件公开
Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide
US 2008119509 A1
申请人: CLAS SOPHIE-DOROTHEE
优先权: 2005
US
4 件公开
CDK INHIBITOR COMPOUNDS
EP 4713096 A1
申请人: ALEKSIA THERAPEUTICS INC
优先权: 2023
CN
EP
WO
3 件公开
Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease
US 11976334 B2
申请人: BAYER AG
优先权: 2017
CN
US
2 件公开
NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME
EP 4385992 A4
申请人: WIGEN BIOMEDICINE TECH SHANGHAI CO LTD
优先权: 2021
CN
EP
2 件公开
4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same
US 2007099951 A1
申请人: DUBE DANIEL
优先权: 2006
US
2 件公开
Inhibitors
US 2007037841 A1
申请人: NAKATANI KAZUHIKO
优先权: 2003
US
4-substituted 2,7-phthalazine compound, and preparation and usethereof
CN 101328172 A
申请人: SHANGHAI INST MATERIA MEDICA
优先权: 2007
CN
Novel use of amine hydrochloride compound
CN 109330998 A
申请人: UNIV TIANJIN SCIENCE & TECH
优先权: 2018
CN
Predictive markers for ATR kinase inhibitors
US 11712440 B2
申请人: BAYER AG
优先权: 2018
US
第 1 / 3 页
上一页
下一页
药物
反馈